- The Myeloma Beacon - https://myelomabeacon.org -
ME vs. MM: Two-Year Cancerversary
By: Kevin Jones; Published: January 17, 2013 @ 12:17 pm | Comments Disabled
The end of this month marks my second anniversary since being diagnosed with multiple myeloma. It's also the end of my induction therapy - a two-year clinical trial with Kyprolis [1] (carfilzomib [2]), Revlimid [3] (lenalidomide), and dexamethasone [4], commonly referred to as CRD, for newly diagnosed patients.
What a long, strange trip it's been - one I'll reflect on briefly for those who aren't familiar with it, then I'll pass along a few tidbits I picked up along the way, and finish with what's next.
By far, the first two to three months after being diagnosed have been the toughest of this journey. For that matter, those first two to three months were probably the toughest of my life (much worse than getting through my teen years, which I previously thought was the worst part of my life). Nothing had ever prepared me for being told I had a terminal disease.
Dealing with the emotional, psychological, and physical impact was quite overwhelming, not to mention just trying to figure out what multiple myeloma was and decide on a treatment within a matter of a few days, or at most weeks.
After being less than impressed with the first doctor I met with, I was fortunate to be referred to Dr. Jakubowiak, a leading multiple myeloma researcher, and get accepted into the CRD trial. This turned out to be a godsend for me. It allowed me to forgo a stem cell transplant, which I was not in favor of at all, and opt for a treatment that proved very effective against my cancer with minimal side effects.
I started treatment in March of 2011 and reached a partial response within one month, a very good partial response after two months, and finally a complete response after 10 months. Since then, it's basically been the monotony of traveling back and forth to the University of Michigan every other week for treatment (thank you whoever invented audio books).
Some of the low points from the past two years:
Some of the high points from the past two years:
Best pieces of advice I received:
The first has been fairly easy to accomplish throughout my treatment period, whereas the second is admittedly easier said than done. There are days when I get treatment or am writing my column that will require more time, but in general I try to limit my cancer time to 15 to 30 minutes a day. When I am able to do so, my psychological state tends to be much better.
Best pieces of advice I might pass along to others:
So now that I'm finishing my induction therapy, what's next?
The big question I'm facing is whether to continue with some sort of maintenance therapy [6]. My doctor has indicated that most of the patients that have been in the CRD trial have opted for maintenance with a lower dose of Revlimid (no Kyprolis or dexamethasone).
On the plus side, studies have shown that Revlimid maintenance can significantly extend a patient's progression-free survival, and in the case of newly diagnosed patients having undergone treatment with novel agents, it may even improve overall survival.
On the down side, I'm concerned about the long-term toxic effects of all the poison I've already pumped into my body, let alone pumping more in for maintenance. There are also concerns regarding secondary cancers [7] with Revlimid, though that appears to be more of a concern with patients who have undergone a stem cell transplant. I'm also concerned whether long-term use of Revlimid could cause me to build up a Revlimid resistance and limit the options I would have for my next line of treatment should I relapse.
Mostly though, I think I would just like to be drug-free for a while.
Peace, and live for a cure.
Kevin Jones is a multiple myeloma patient and columnist at The Myeloma Beacon. You can view a list of his columns here [8].
If you are interested in writing a regular column for The Myeloma Beacon, please contact the Beacon team at .
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/headline/2013/01/17/me-vs-mm-two-year-cancerversary/
URLs in this post:
[1] Kyprolis: https://myelomabeacon.org/tag/kyprolis/
[2] carfilzomib: https://myelomabeacon.org/tag/carfilzomib/
[3] Revlimid: https://myelomabeacon.org/resources/2008/10/15/revlimid/
[4] dexamethasone: https://myelomabeacon.org/resources/2008/10/15/dexamethasone/
[5] Agent D: https://myelomabeacon.org/headline/2012/05/15/me-vs-mm-agent-d/
[6] maintenance therapy: https://myelomabeacon.org/tag/maintenance-therapy/
[7] secondary cancers: https://myelomabeacon.org/tag/secondary-cancer/
[8] here: https://myelomabeacon.org/author/kevin-jones/
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.